Alnylam Reviews

3.6
Rating Trends
Recommend to a friend
Approve of CEO
Alnylam CEO and Director John M. Maraganore
John M. Maraganore
6 Ratings
  • Helpful (2)

    more open in the start up years

    Former Employee - Anonymous Employee in Waltham, MA
    Former Employee - Anonymous Employee in Waltham, MA

    I worked at Alnylam full-time (More than 8 years)

    Pros

    really great science, a lot of good people working there and despite some typical for the industry stumbles they have built quite an impressive track record. Some of the micro-cultures are really great

    Cons

    the place is pretty vertically organized for a company of that size, like all public companies there is a high degree of confidentiality around some issues and some of the micro-cultures are really cut throat

    Advice to Management

    The bell curve for merit increases can do more harm that good a hyper competitive environment is not helpful or innovation or morale.


Alnylam Interviews

Interview Experience

Interview Experience

66%
0%
33%

Getting an Interview

Getting an Interview

66%
33%

Interview Difficulty

2.7
Average

Interview Difficulty

Hard

Average

Easy
  1. Helpful (1)  

    Scientist Interview

    Anonymous Employee
    No Offer

    Interview

    Rigorous but great experience. They know exactly what they are looking fur in the candidate. Everyone was candid and curious to know what your strengths are and what you would bring to the table.

    Interview Questions

Alnylam Awards & Accolades

Something missing? Add an award
Top Places to Work Globe 100 , Boston Globe, 2008

Additional Info

Unlock Profile
Website www.alnylam.com
Headquarters Cambridge, MA
Size 150 to 499 Employees
Founded 2003
Type Company - Public (ALNY)
Industry Biotech & Pharmaceuticals
Revenue $50 to $100 million (USD) per year
Competitors Pfizer, Biovail

Call it The Silence of the Genes. Alnylam Pharmaceuticals runs interference with RNA to prevent disease. RNA interference (RNAi) technology developed by the biotech firm can selectively shut off harmful genes. The company is developing a pipeline of candidates both individually and through collaborations with other drugmakers. Its disease targets include rare genetic disorder ATTR (transthyretin-mediated amyloidosis) and RSV (respiratory syncytial virus), a common childhood viral infection. Additional R&D programs target neurological disorders, cardiovascular ... More

Work at Alnylam? Share Your Experiences

Alnylam

 
Click to Rate
or